Company Overview of Crucell N.V.
Crucell N.V. operates as a biopharmaceutical company that discovers, develops, manufactures, and markets vaccines, proteins, and antibodies against infectious diseases in paediatric, travel and endemic, and respiratory fields. It offers liquid pentavalent vaccines, recombinant hepatitis B vaccines, aluminum-free hepatitis A vaccines, live attenuated typhoid fever vaccines, drinkable vaccines, and virosomal adjuvanted influenza vaccines, as well as vaccines for protection against measles and rubella in children, adolescents, and adults. The company also develops an anti-influenza antibody for neutralizing group 2 influenza A viruses; and licenses its technologies to the biopharmaceutical indu...
Leiden, 2333 CN
Founded in 1993
Key Executives for Crucell N.V.
Chairman of Management Board, Chief Executive Officer, President and Managing Director
Chief Executive Officer of R&D Center - PER.C6® Technology
Chief Scientific Officer, Director of the Crucell Vaccine Institute and Member of the Management Board
Chief Strategy Officer, Executive Vice President of Business Development and Head of the Protein Business Unit
Executive Vice President of Development
Compensation as of Fiscal Year 2014.
Crucell N.V. Key Developments
Crucell Presents at World Vaccine Congress Washington 2013, Apr-17-2013 12:50 PM
Mar 26 13
Crucell Presents at World Vaccine Congress Washington 2013, Apr-17-2013 12:50 PM. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Speakers: Eirikur Saeland, Senior Scientist Immunology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries